Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphoid leukemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    380 result(s) found for: Lymphoid leukemia. Displaying page 2 of 19.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-001099-49 Sponsor Protocol Number: CLOSE(PS-CLL-001) Start Date*: 2018-07-12
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Clonal evolution in progressive CLL patients harboring subclonal TP53 aberrations treated with ibrutinib first-line
    Medical condition: Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000243-10 Sponsor Protocol Number: Hx-CD20-407 Start Date*: 2007-05-16
    Sponsor Name:Glaxo SmithKline Research and Development Limited
    Full Title: An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with fludarabine and cyclophosphamide, in patients with previ...
    Medical condition: B-cell Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001015-28 Sponsor Protocol Number: LLC 2007 SA Start Date*: 2007-07-27
    Sponsor Name:CHU TOURS
    Full Title: Single-agent rituximab as maintenance treatment versus observation after combined induction immunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) in patients older than 65 years...
    Medical condition: The trial compares single-agent rituximab as maintenance treatment versus observation after combined immunochematherapy with fludarabine, cyclophosphamide and rituximab (FCR) in patients older than...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009310 CLL LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009034-32 Sponsor Protocol Number: 4/2009 Start Date*: 2009-06-28
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: R788 as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
    Medical condition: Chronic Lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005465-19 Sponsor Protocol Number: DSC/06/2357/21 Start Date*: 2007-02-09
    Sponsor Name:ITALFARMACO
    Full Title: Open label, uncontrolled, pilot, phase II study of histone-deacetylase inhibitor ITF2357 administered orally to subjects with chronic lynphocytic leukemia (CLL) refractory/relapsed after convention...
    Medical condition: Chronic lynphocytic leukemia (CLL) refractory/relapsed after conventional chemotherapy or relapsed after autologous bone marrow transplantation
    Disease: Version SOC Term Classification Code Term Level
    6.1 10008958 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002601-40 Sponsor Protocol Number: CD20-0703 Start Date*: 2008-09-25
    Sponsor Name:LFB BIOTECHNOLOGIES
    Full Title: Open, non-controlled, multicentre, first-in-man study using escalating doses of LFB-R603 in patients with advanced stage B-Chronic lymphocytic leukemia
    Medical condition: B-Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    11 10008960 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004409-30 Sponsor Protocol Number: PS-CLL-009 Start Date*: 2021-05-27
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Venetoclax and delayed rituximab with ibrutinib consolidation aiming at undetectable minimal residual disease (uMRD) in treatment-naïve patients with chronic lymphocytic leukemia (CLL)
    Medical condition: Previously Untreated Chronic Lymphophatic Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000722-96 Sponsor Protocol Number: PS-CLL-005 Start Date*: 2022-02-09
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Lymph Node Microenvironment Modifications in Patients with CLL Treated with Venetoclax-based regimens
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000633-17 Sponsor Protocol Number: ALL2922 Start Date*: 2022-08-09
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Combination of Ponatinib Plus Chemotherapy As Frontline Treatment For Patients With BCR/ABL1-Like Acute Lymphoblastic Leukemia (BCR/ABL1-Like ALL) - BALLik
    Medical condition: Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-006048-15 Sponsor Protocol Number: ALL2820 Start Date*: 2021-05-03
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherap...
    Medical condition: Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006300-27 Sponsor Protocol Number: MC-ASP.6/INF Start Date*: 2009-08-12
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphoblastic leukaemia - Phase II Clinical Trial -
    Medical condition: Acute lymphoblastic leukaemia (ALL) is a clonal disease resulting from genetic mutations and transformation of a single early progenitor lymphoid cell. Uncontrolled expansion of leukaemic blasts in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-005049-36 Sponsor Protocol Number: CAMPATH Start Date*: 2005-02-03
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: CAMPATH-1H MONOCLONAL ANTIBODY AS MANTEINANCE THERAPY AFTER FLUDARABINE AND CYCLOPHOSPHAMIDE COMBINATION REGIMEN AS 2ND LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Medical condition: B-CLL DISEASE
    Disease: Version SOC Term Classification Code Term Level
    Nd 10008958 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001824-30 Sponsor Protocol Number: BEN-CAM Start Date*: 2008-06-17
    Sponsor Name:Associazione Malattie Sangue Onlus
    Full Title: Phase II study of the combination Bendamustine and sc Alemtuzumab for patients with refractory or relapsed B-cell chronic lynphocytic leukemia
    Medical condition: patients whit LLC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008958 Chronic lymphocytic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001823-71 Sponsor Protocol Number: LEN-CAM Start Date*: 2008-08-26
    Sponsor Name:Associazione Malattie Sangue ONLUS
    Full Title: Phase II study of the combination of Lenalidomide and Alemtuzumab as consolidation in patients who responded to a previus chemotherapeutic regimen administered for relapsed or refractory Chronic Ly...
    Medical condition: CLL patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008958 Chronic lymphocytic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-018519-14 Sponsor Protocol Number: IEO S523/110 Start Date*: 2011-01-13
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Rituximab-2cda + Rituximab maintenance in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma
    Medical condition: CHRONIC LYMPHATIC LEUKEMIA, LYMPHOCYTIC LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052178 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003912-28 Sponsor Protocol Number: ALL2620 Start Date*: 2021-01-28
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Ponatinib for the management of minimal residual disease (MRD) and hematologic relapse in adult Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients.
    Medical condition: Ph+ Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002476-15 Sponsor Protocol Number: GIMEMALLC0405 Start Date*: 2005-07-28
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: Phase II pilot trial to evaluate the efficacy and safety of a first-line combined therapeutic approach for young (> = 60 years old) CLL patients with advanced and progressive disease stratif...
    Medical condition: CLL patients (diagnosis of CLL according to NCI criteria) with the following characteristics: Advanced stage or progressive disease with at least 2 clinical features of activity. Previously untreat...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011078-14 Sponsor Protocol Number: 09_DOG06_99 Start Date*: 2009-11-27
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: A single arm phase II study to investigate the use of Lenalidomide in the treatment of patients with early stage CLL associated with poor prognostic factors.
    Medical condition: Untreated early stage Chronic Lymphocytic Leukaemia (CLL) (Binet stage A) with poor prognostic factors.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008958 Chronic lymphocytic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000792-14 Sponsor Protocol Number: IPC 2009-004 Start Date*: 2011-06-14
    Sponsor Name:Institut Paoli-Calmettes
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060391 Leukaemia lymphocytic chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003012-35 Sponsor Protocol Number: HM07/8281 Start Date*: 2012-06-12
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: CLARET: CLL Levels following Alemtuzumab in Responders to Early Therapy: A randomised, phase III trial to assess alemtuzumab consolidation therapy in patients with chronic lymphocytic leukaemia (CL...
    Medical condition: Chronic lymphocytic leukaemia (CLL).
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 00:35:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA